MedTrace Logo

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 366

Last updated 2022-03-25

Study results available
· View outcomes & findings →

Summary

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

Conditions

  • Active Non-segmental Vitiligo

Interventions

DRUG

PF-06651600

Induction dose 1. Oral tablet taken QD

DRUG

PF-06651600

Induction dose 2. Oral tablet taken QD

DRUG

PF-06651600

Maintenance dose A. Oral tablet taken QD

DRUG

PF-06651600

Maintenance Dose B. Oral tablet taken QD

DRUG

PF-06651600

Maintenance Dose C. Oral tablet taken QD

DRUG

placebo

placebo

DRUG

PF06700841

Oral tablet taken QD

DEVICE

narrow-band UVB phototherapy

Phototherapy will be combined with PF-06651600

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-26
Primary Completion
2021-02-05
Completion
2021-02-05
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Germany
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03715829 on ClinicalTrials.gov